Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ghazi Nsouli"'
Autor:
Rajaa Chatila MD, Joseph Mansour MD, Anas Mugharbil MD, Ghazi Nsouli MD, Lana O’Son MD, Edouard Sayad MD, Mary E. Deeb PhD
Publikováno v:
Cancer Control, Vol 28 (2021)
Background Scarce data exist about colorectal cancer (CRC) presentation and outcomes in Lebanon. The aim of this study is to describe the characteristics of Lebanese patients diagnosed with colorectal cancer, particularly the method of detection, age
Externí odkaz:
https://doaj.org/article/3867831d0dd84261b381c66dfb68a368
Publikováno v:
Pharmacogenomics. 23:487-492
Talazoparib is an oral PARP inhibitor approved for locally advanced/metastatic breast cancer. There is no consensus, however, as to whether it is better used as a first-line treatment or after other therapies in patients with gBRCA mutations. In fact
Publikováno v:
Cureus.
Publikováno v:
Pharmacogenomics. 23(8)
Talazoparib is an oral PARP inhibitor approved for locally advanced/metastatic breast cancer. There is no consensus, however, as to whether it is better used as a first-line treatment or after other therapies in patients with
Autor:
Nada Ghosn, Lara Bazzi, Walid Ammar, Ahmad Hijazi, Ghazi Nsouli, Alissar Rady, Mamunur Rahman Malik, Wasiq Khan, Majd Saleh, Ahmad Al Samadi, Pierre Zalloua, Ebstissam Ismail, Nisrine Jammal, Firass Abiad, Lina Mroueh, Amgad Elkholy, Pamela Mrad
Publikováno v:
Influenza and Other Respiratory Viruses
Background Given the sparse information on the burden of influenza in Lebanon, the Ministry of Public Health established a sentinel surveillance for severe acute respiratory infections (SARI) to identify the attribution of influenza to reported cases
Autor:
Rahif Jalloul, Ali Shamseddine, Fadi Farhat, Ghazi Nsouli, Sally Temraz, Joseph Kattan, Nadine Haddad, Nizar Bitar, Hassan A. Hatoum, Khaled Ibrahim
Publikováno v:
Clinical Breast Cancer. 11:384-389
We assessed the efficacy and safety of a liposomal cisplatin (lipoplatin) and vinorelbine combination in metastatic breast cancer (MBC). Thirty-five patients were treated. The objective response rate was 53.1% and the median survival time was 22 mont
Autor:
Zaher K. Otrock, Jawad A. Makarem, Mireille M. Kattar, Ali T. Taher, Ali Shamseddine, Ghazi Nsouli
Publikováno v:
Digestive Diseases and Sciences. 52:1589-1591